Justin B. Klee - Jan 6, 2022 Form 3 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: Co-Chief Executive Officer, Director
Signature: /s/ Justin Klee
Stock symbol: AMLX
Transactions as of: Jan 6, 2022
Transactions value $: $0
Form type: 3
Date filed: 1/6/2022, 04:06 PM
Next filing: May 6, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AMLX	Common Stock						2.48M	Jan 6, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AMLX	Stock Option (Right to Buy)							Jan 6, 2022	Common Stock	335K	$0.37	Direct	F1
holding	AMLX	Stock Option (Right to Buy)							Jan 6, 2022	Common Stock	100K	$1.57	Direct	F2
holding	AMLX	Stock Option (Right to Buy)							Jan 6, 2022	Common Stock	200K	$7.57	Direct	F3
holding	AMLX	Series C-1 Preferred Stock							Jan 6, 2022	Common Stock	4.87K		Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	6,977 shares subject to such stock option vested and became exercisable on March 16, 2018 and the remainder of the shares vest in monthly installments of 6,969 shares for a period of 47 months after the vesting commencement date.
F2	25,012 shares subject to such option vested and became exercisable on February 26, 2021 and the remainder of the shares vest in monthly installments of 2,083 shares thereafter.
F3	50,024 shares subject to such option shall vest and become exercisable on February 19, 2022 and the remainder of the shares vest in monthly installments of 4,166 shares thereafter.
F4	Each share of Series C-1 preferred stock is convertible on a one-for-one basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The Series C-1 Preferred stock has no expiration date.